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Effect of Continuing Olanzapine vs Placebo on Relapse
Among PatientsWith Psychotic Depression in Remission
The STOP-PD II Randomized Clinical Trial
Alastair J. Flint, MB; Barnett S. Meyers, MD; Anthony J. Rothschild, MD; Ellen M.Whyte, MD; George S. Alexopoulos, MD; Matthew V. Rudorfer, MD;
Patricia Marino, PhD; Samprit Banerjee, PhD; Cristina D. Pollari, MPH; YiyuanWu, MS; Aristotle N. Voineskos, MD, PhD; Benoit H. Mulsant, MD;
for the STOP-PD II Study Group
IMPORTANCE Psychotic depression is a severely disabling and potentially lethal disorder.
Little is known about the efficacy and tolerability of continuing antipsychotic medication for
patients with psychotic depression in remission.
OBJECTIVE To determine the clinical effects of continuing antipsychotic medication once an
episode of psychotic depression has responded to combination treatment with an
antidepressant and antipsychotic agent.
DESIGN, SETTING, AND PARTICIPANTS Thirty-six week randomized clinical trial conducted
at 4 academic medical centers. Patients aged 18 years or older had an episode of psychotic
depression acutely treated with sertraline plus olanzapine for up to 12 weeks andmet criteria
for remission of psychosis and remission or near-remission of depressive symptoms
for 8 weeks before entering the clinical trial. The study was conducted fromNovember 2011
to June 2017, and the final date of follow-up was June 13, 2017.
INTERVENTIONS Participants were randomized either to continue olanzapine (n = 64) or
switch from olanzapine to placebo (n = 62). All participants continued sertraline.
MAIN OUTCOMES ANDMEASURES The primary outcomewas risk of relapse. Main secondary
outcomes were change in weight, waist circumference, lipids, serum glucose, and
hemoglobin A1c (HbA1c).
RESULTS Among 126 participants who were randomized (mean [SD] age, 55.3 years
[14.9 years]; 78 women [61.9%]), 114 (90.5%) completed the trial. At the time of
randomization, the median dosage of sertraline was 150mg/d (interquartile range [IQR],
150-200mg/d) and themedian dosage of olanzapine was 15 mg/d (IQR, 10-20mg/d).
Thirteen participants (20.3%) randomized to olanzapine and 34 (54.8%) to placebo
experienced a relapse (hazard ratio, 0.25; 95% CI, 0.13 to 0.48; P < .001). The effect of
olanzapine on the daily rate of anthropometric andmetabolic measures significantly differed
from placebo for weight (0.13 lb; 95% CI, 0.11 to 0.15), waist circumference (0.009 inches;
95% CI, 0.004 to 0.014), and total cholesterol (0.29mg/dL; 95% CI, 0.13 to 0.45) but was
not significantly different for low-density lipoprotein cholesterol (0.04mg/dL; 95% CI, −0.01
to 0.10), high-density lipoprotein cholesterol (−0.01 mg/dL; 95% CI, −0.03 to 0.01),
triglyceride (−0.153mg/dL; 95% CI, −0.306 to 0.004), glucose (−0.02mg/dL; 95% CI, −0.12
to 0.08), or HbA1c levels (−0.0002mg/dL; 95% CI, −0.0021 to 0.0016).
CONCLUSIONS AND RELEVANCE Among patients with psychotic depression in remission,
continuing sertraline plus olanzapine compared with sertraline plus placebo reduced the risk
of relapse over 36 weeks. This benefit needs to be balanced against potential adverse effects
of olanzapine, including weight gain.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01427608
JAMA. 2019;322(7):622-631. doi:10.1001/jama.2019.10517
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M ajordepressivedisorderwithpsychotic features (psy-chotic depression) is a severely disabling disorder,with high risk of suicide.1,2 Meta-analyses support
the use of either electroconvulsive therapy or pharmaco-
therapywith thecombinationof anantidepressantwithanan-
tipsychotic agent for the acute treatment of psychotic
depression.3,4 Once an episode ofmajor depression responds
to antidepressantmedication, the antidepressant needs to be
continued to prevent relapse and recurrence of depression.5
However, it is not known whether antipsychotic medication
needs to be continued once an episode of psychotic depres-
sion has responded to combined antidepressant-antipsy-
chotic treatment. This is a critical question because prema-
ture discontinuation of antipsychoticmedication has the risk
of relapseof a severe life-threateningdisorder. In contrast, the
unnecessary continuation of an antipsychotic agent exposes
a patient to potentially serious adverse effects.
The Study of the Pharmacotherapy of Psychotic Depres-
sion (STOP-PD) was the first randomized clinical trial (RCT)
fundedby theNational InstituteofMentalHealth (NIMH) toex-
amine the efficacy and tolerability of combination pharmaco-
therapy using a serotonergic antidepressant and a second-
generation antipsychotic agent for the acute treatment of
psychoticdepression.6Olanzapineplus sertralinewasmoreef-
ficacious than olanzapine plus placebo, but both treatments
were associatedwith an increase in weight and lipids over the
12-weekstudy.6Theprimarygoalof thecurrentSTOP-PDII trial
was to assess the risks and benefits of continuing antipsy-
chotic medication in younger and older patients with psy-
chotic depression, once the depressive episode had re-
spondedtotreatmentwithsertralineplusolanzapine.Thestudy
tested the hypotheses that the combination of sertraline plus
olanzapine is associated with lower risk of relapse and higher
weightandtotalcholesterolandtriglyceridelevels thanthecom-
bination of sertraline plus placebo.
Methods
The trialdesignandmethodshavebeenpublishedpreviously.7
The study protocol is provided in Supplement 1. This article
reports the resultsof the first andsecondaims listed in thepro-
tocol that pertain to the benefits and risks of continuing anti-
psychoticmedication among patientswith psychotic depres-
sion inremission.Findings thatpertain toadditionalaims listed
in theprotocol,namely theassociationbetweenageandchange
in weight and metabolic measures and the association of ge-
neticpolymorphismswithoutcomes,arenotpresentedherein.
Participants
Thestudywasconductedat4medicalcenters (UniversityHealth
Network,Toronto;UniversityofMassachusettsMedicalSchool;
University of Pittsburgh School ofMedicine; andWeill Cornell
Medical College) between November 2011 and June 2017, and
the final date of follow-upwas June 13, 2017 (Figure 1). Partici-
pantsafety issuesandqualityassurancewereoverseenbyadata
and safety monitoring board appointed by the NIMH. Race/
ethnicity were collected via participant self-report using fixed
categories to satisfy theNational InstitutesofHealthPolicyand
Guidelines on the Inclusion of Women and Minorities as Sub-
jects in Clinical Research. Using procedures approved by local
institutional reviewboards,written informed consentwas ob-
tained from all participants or their substitute decisionmaker
prior to the initiation of any research procedures.
The study had 3 phases: acute, stabilization, and random-
ization.At thetimeofenrollment intheacutephaseof thestudy,
participantswerebetweentheagesof18and85years,metStruc-
turedClinical Interview forDiagnostic andStatisticalManual of
Mental Disorders (Fourth Edition, Text Revision) (DSM-IV-TR)8
criteria for a currentmajor depressive episodewith at least one
associated delusion (with or without hallucinations), and had
a 17-itemHamiltonDepressionRatingScale (HDRS)9 total score
of 21 or higher. Inclusion criteria for a delusion were a score of
3 or higher on the delusion severity item of the Schedule for
Affective Disorders and Schizophrenia10 (delusion definitely
present)andascoreof2orhigheronanyofthe3convictionitems
of the Delusion Assessment Scale11 (the participant is certain
a belief is true and does not change the belief in response to re-
ality testing by the interviewer). The study’s exclusion criteria
includedcurrentor lifetimeDSM-IV-TRcriteriaforanyotherpsy-
choticdisorder,bipolardisorder,or intellectualdisability;DSM-
IV-TRcriteriaforcurrentbodydysmorphicdisorderorobsessive-
compulsivedisorder;DSM-IV-TRdefineddementiaprecedingthe
index episode of depression or a 26-item informant question-
naireoncognitivedecline in theelderly (IQCODE)12meanscore
of 4 or higher at acute phase baseline;DSM-IV-TR defined sub-
stanceabuseordependencewithinthepreceding3months; type
1 diabetesmellitus; neurologic disease thatmight affect neuro-
muscular function;andunstablephysical illness,althoughmany
of the studyparticipants had stable chronic physical problems.
In theopen-label acutephase, participants receiveda com-
bination of sertraline (target dose, 150-200mg/d, dispensed in
50-mg pills) plus olanzapine (target dose, 15-20 mg/d, dis-
pensed in 5-mg pills). Olanzapine was chosen because it is the
only antipsychotic agentwith established efficacy in combina-
tion therapy in both younger and older personswith psychotic
depression.3,4,6 Participants entered the open-label stabiliza-
tionphase as soonas theymet criteria for remission, definedas
theabsenceofdelusionsandhallucinationsanda17-itemHDRS
score of 10 or less for 2 consecutiveweeks. In addition, partici-
pantswhomet criteria for “near remission” following 12weeks
of acute treatment were also eligible to enter the stabilization
phase.Near remissionwas defined as the absence of delusions
Key Points
Question Does continuing antipsychoticmedication reduce the risk
of relapse among patientswith psychotic depression in remission?
Findings In this 36-week randomized clinical trial that included
126 persons aged 18 years or older, 13 participants (20.3%)
randomized to sertraline plus olanzapine and 34 (54.8%) to
sertraline plus placebo experienced a relapse, a difference that
was statistically significant.
Meaning For patients with psychotic depression in remission,
continuing olanzapine reduced the 36-week risk of relapse.
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andhallucinations, anHDRS score of 11 to 15with 50%ormore
reductioninbaselineHDRSscore,andbeingratedas“verymuch
improved” or “much improved” on the Clinical Global
Impression13 scale.At theendof the8-weekstabilizationphase,
participants who still met full-remission or near-remission cri-
teriafollowingtreatmentwithsertralineplusolanzapineandwho
had a Mini-Mental State Examination (MMSE)14 score of 24 or
higher were eligible for the 36-week RCT.
Figure 1. Flow of Participants in the Study of the Pharmacotherapy of Psychotic Depression II (STOP-PD II)
350 Patients consented to participate
and were assessed for eligibility
81 Excluded
60 Not eligible
16 Withdrew consent
5 Other reasons
21 Not randomized
12 Not eligible
9 Did not consent to randomization
33 Excluded (symptoms did not remit)
195 Completed acute treatment
74 Discontinued treatment
31 Withdrew consent
21 Insufficient response/clinical worsening
7 Not appropriate for research participationa
5 Adverse events
1 Medical event
9 Other reasons
147 Completed stabilization phase
15 Discontinued treatment
4 Clinical worsening
2 Withdrew consent
1 Died (not by suicide)
1 Not appropriate for research participationa
7 Other reasons
126 Randomized
64 Included in the primary analysis
43 Completed in remission or
near remission
13 Relapsed
8 Discontinued
1 Died (not by suicide)
5 Withdrew consent
1 Moved
1 Transportation problems
62 Included in the primary analysis
24 Completed in remission or
near remission
34 Relapsed
4 Discontinued
1 Medical event
3 Withdrew consent
269 Started open-label treatment
with sertraline and olanzapine
162 Entered the stabilization open-label
treatment with sertraline and olanzapine
64 Randomized to receive sertraline and
olanzapine
59 Received treatment as randomized
5 Did not receive treatment as
randomized
3 Discontinued
2 Switched to open label olanzapine
62 Randomized to receive sertraline
and placebo
60 Received treatment as randomized
2 Did not receive treatment as
randomized
1 Discontinued
1 Switched to open label olanzapine
a Examples of “not appropriate for
further research participation”:
repeated nonadherence with
research assessments or repeated
nonadherence with study
medications during the “open-label”
acute and stabilization phases of
the study.
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Randomization
Randomizationwas computer-generatedwith a 1:1 allocation
ratio and a block size range of 4 to 8, stratified by age (18-59
yearsvs60-85years), remissionvsnear remissionstatusat ran-
domization, and study site.
Intervention
All participants continued to takeopen-label sertraline for the
duration of the trial. They were randomized under double-
blind conditions to either continueolanzapine or switch from
olanzapine to identically appearingplacebopills over a4-week
taperofolanzapine.Thedouble-blind taperwasconductedac-
cording to a schedule for the substitution of blinded olanza-
pine or placebo for open-label olanzapine, based on the num-
ber of olanzapine pills that the participant was taking at the
timeof randomization (Supplement 1). Participants in the trial
were assessed weekly for the first 8 weeks and once every 4
weeks thereafter until study completion at week 36, relapse,
or early termination. If a participant chose to discontinue one
or both study medications, including replacing study medi-
cation(s)withotherpsychotropicmedication, everyeffortwas
made to continue research assessments for the entire course
of randomizedtreatmentoruntil relapse,whichevercamefirst.
Outcomes
Primary Outcome: Relapse
Riskof relapsewas theprimaryoutcome.Relapse criteriawere
broad, to reflect a range of clinically relevant outcomes of
psychotic depression. Declaring relapse required at least 1 of
the following: (1) enoughStructuredClinical Interview for the
DSM (SCID)–rated symptoms tomeet criteria for aDSM-IVma-
jor depressive episode; (2) 17-itemHDRS score of 18 or higher;
(3) SCID-rated psychosis (delusions or hallucinations);
or (4) other significant clinical worsening, defined as having
a suicide plan or attempting suicide, developing SCID-rated
symptoms of mania or hypomania, or being hospitalized in
a psychiatric unit. Althoughpatientswith a diagnosis of bipo-
lar disorder were not eligible for the study, psychotic depres-
sion in younger adults may predict subsequent development
ofmaniaorhypomania.1Participantswithrelapse left thestudy
andwere treatedunder usual care conditions.Whenever pos-
sible, investigators remained blind to the randomization as-
signment of participants after they left the study.
Secondary Outcomes: Anthropometric andMetabolic Measures
Weight and waist circumference were measured at each
study visit. Fasting cholesterol and triglycerides levels, as
well as fasting glucose and hemoglobin A1c (HbA1c), were
measured at the RCT baseline, once every 8 weeks thereafter,
and at study termination.
OtherMeasures of Tolerability
ResearchpsychiatristsmeasuredRCTbaseline extrapyramidal
symptoms, every 4 weeks thereafter, and at study termina-
tion. Parkinsonism was measured with the Simpson-Angus
Scale15 (total score range, 0-40, with higher scores indicating
greater severity), akathisia with the Barnes Akathisia scale16
(score rangeon theglobal clinical assessment,0-5,withhigher
scores indicatinggreater severity), and tardivedyskinesiawith
theAbnormal InvoluntaryMovementsScale17 (score range,0-5
on each of 10 items, with higher score on each item indicating
greater severity). Incident akathisia was defined as a Barnes
global clinical assessment score16 of 0 at RCT baseline and 2 or
higher at any subsequent assessment. Incident tardive dyski-
nesiawasdefinedaccordingtoSchooler-Kaneresearchcriteria.18
Adverseeffectswereelicited fromparticipantsat eachvisit
with theUdvalg forKliniskeUndersogelser19 scale (score range,
0-3 on each of 48 items, with higher score on each item indi-
cating greater severity).With the exceptionofweight gain and
weight loss, an adverse effect was considered present if there
was a 2-point increase from RCT baseline or a score of 3 or 4
and an increase from baseline. Adverse weight gain was op-
erationalizedasmeasuredweightofmore than7%higher than
premorbid weight and adverse weight loss was operational-
ized asmeasuredweightmore than 7% lower thanpremorbid
weight. Premorbid weight, defined as the most recent known
weightprior toonset of the current episodeofdepression,was
used so that we could account for depression-related weight
loss. Incident falls were queried at each study visit. In addi-
tion,werecordedseriousadverseevents that resulted indeath,
life-threatening problems including suicide attempts, persis-
tent or significant disability or incapacity, or hospitalization.
Power Analysis
We calculated that a sample of 176 randomized participants
would provide 80% power to detect a 20% difference in risk
of relapse between randomized groups and up to 15% attri-
tion.A20%differencewouldmean that 5patientswouldneed
tobe treatedwitholanzapine toprevent 1 caseof relapse, a fig-
ure that is consistent with 1 year of continuation of antide-
pressant treatment fornonpsychoticdepression.20Threeyears
after the start of recruitment, however, a revised sample size
of 128 randomizedparticipantswas approvedbyNIMHand its
data and safetymonitoring boardbecauseof ahigher than an-
ticipated overall risk of relapse.
Statistical Analyses
Analyses included all randomized participants. The primary
hypothesiswas testedwith aCoxproportional hazardsmodel
that compared riskof relapseacross treatmentgroups.TheCox
model included treatment group and the 3 aforementioned
stratification variables as covariates. The proportional haz-
ards assumption of the Cox models was confirmed by visual
inspection of complementary log-log plots and tests of corre-
lation of the Schoenfeld residualwith time. In addition, a Cox
model that excluded participants who had elected to discon-
tinue either sertraline, olanzapine or placebo, or both but re-
mained in the study for research assessmentswas performed
as a post hoc sensitivity analysis.
Linear mixed models were used to analyze the anthropo-
metric and metabolic measures. Each of these models in-
cluded aparticipant-level random intercept and randomslope
(with continuous time) and fixed effects for site, time, treat-
mentgroup,andtreatment × timeinteraction.APoissonmixed-
effects regressionwith an overdispersion parameter was used
to analyze Simpson-Angus Scale15 scores. Thismodel included
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a participant-level random intercept and fixed effects for site,
time, treatment group, and treatment × time interaction.
Because of relapse, the frequency of early termination
was higher in the sertraline-placebo group than with the
sertraline-olanzapine group resulting in missed outcomes.
Ourmixedmodels provide valid inference under themissing-
at-random assumption. However, to investigate bias due
to nonignorable missing patterns, pattern mixture model-
ing was performed for each outcome. They examined
whether the treatment effect changed with the pattern
of early termination and, if so, corrected for the bias due to
this pattern. Pattern mixture models indicated that esti-
mates from the linear mixed models and Poisson model were
likely not biased, with the exception of triglycerides. In the
case of triglycerides, pattern-mixture-averaged estimates21
are reported.
To examine for the possible effect of a statin or hypogly-
cemicagenton linearmixed-modelmetabolic results, posthoc
sensitivityanalyseswereperformed,whereby if adrug in these
categories was started or changed during the trial, pertinent
metabolic data from that point on were excluded from the
mixed model.
Table 1. Characteristics of Study Participants
Baseline Characteristics
No. (%) of Participants
Sertraline + Olanzapine (n = 64) Sertraline + Placebo (n = 62)
Sociodemographic
Age, mean (SD), y 55.0 (15.1) 55.7 (14.9)
18-59 36 (56.2) 36 (58.1)
≥60 28 (43.8) 26 (41.9)
Sex
Men 27 (42.2) 21 (33.9)
Women 37 (57.8) 41 (66.1)
Race
White 54 (84.4) 49 (79.0)
Black 6 (9.4) 9 (14.5)
Othera 4 (6.3) 4 (6.5)
Hispanic ethnicity 6 (9.4) 9 (14.5)
Marital
Single 19 (29.7) 15 (24.2)
Married 28 (43.8) 35 (56.5)
Separated or divorced 12 (18.8) 7 (11.3)
Widowed 5 (7.8) 5 (8.1)
Education, mean (SD), y 14.4 (3.2) 13.4 (3.9)
Living arrangements
With others 46 (71.9) 49 (79.0)
Alone 17 (26.6) 10 (16.1)
Senior residence 1 (1.6) 1 (1.6)
Clinical Characterstics at Acute Phase Baseline
Inpatient status at acute phase enrollment 41 (64.1) 46 (74.2)
Study site
Cornell University 16 (25.0) 15 (24.2)
University of Massachusetts 15 (23.4) 14 (22.6)
University of Pittsburgh 9 (14.1) 10 (16.1)
University Health Network, Toronto 24 (37.5) 23 (37.1)
≥2 Lifetime depressive episodes 47 (73.4) 47 (75.8)
Duration of current episode of depression,
median (IQR), mo
5.5 (3-12) 5.5 (2-12) [n=60]
Age of onset of first major depressive episode,
median (IQR), y
37 (24-50) [n=62] 35 (18-51) [n=61]
Suicide attempt in current episode 13 (20.3) 12 (19.4)
Treatment resistance in current episodeb 3 (4.7) 5 (8.1)
Diagnoses
Hyperlipidemia 18 (29.0) 19 (29.7)
Hypertension 17 (26.6) 22 (35.5)
Diabetes 12 (18.8) 15 (24.2)
Premorbid weight, mean (SD), lbc 166.6 (34.6) [n=60] 171.4 (40.2) [n=59]
Abbreviation: IQR, interquartile
range.
SI conversion factor: To convert lb to
kg, multiply by 0.45.
a Includes American Indian or Alaska
Native, Asian, Native Hawaiian or
other Pacific Islander, and unknown
or not reported.
bDefined as an antidepressant plus
antipsychotic combination rating
score of 3 or higher on the
Antidepressant Treatment History
Form23 or 7 or more treatments
of electroconvulsive therapy
during the current episode of
psychotic depression.
c Defined as themost recent known
weight before onset of the current
episode of depression.
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Post hoc analyses compared randomized groups on the
number of participants who experienced an incident high
metabolic value.
The incidenceof akathisia and tardivedyskinesia, the fre-
quency of Udvalg for Kliniske Undersogelser19 scale adverse
effects, and the frequency of falls and serious adverse events
are reported descriptively.
Analyses were conducted using SAS version 9.4 (SAS In-
stitute Inc). All statistical tests were 2-sided, performed at an
overall 5% level of significance forprimaryandsecondaryout-
comes. P values for multiple secondary outcomes were ad-
justedusing theHolmstepdownmethod.22 Because these ad-
justments were post hoc, the interpretation of secondary
outcomes should be considered exploratory.
(To convert cholesterol frommg/dL to mmol/L, multiply
by0.0259;glucose frommg/dLtommol/L,multiplyby0.0555;
triglycerides frommg/dL tommol/L,multiply by 0.0113; lb to
kg, multiply by 0.45; and in to cm, multiply by by 2.54.)
Results
Participant Characteristics
Of the269participantswhoenrolled in thestudy, 126were ran-
domized (64 to sertraline-olanzapine and 62 to sertraline-
placebo) (Figure 1). Characteristics of the randomized groups
are shown in Table 1 and Table 2.
Primary Outcome
A relapse occurred in 13 of 64 participants (20.3%) in the ser-
traline-olanzapinegroupand34of62 (54.8%) in thesertraline-
placebogroup.Table 3 lists the relapse events in each random-
ized group. In the multivariable Cox proportional hazards
model, there was a statistically significant difference in risk
of relapsebetweenrandomizedgroups (hazard ratio [HR],0.25
[95% CI, 0.13-0.48], P < .001), controlling for age group (HR,
0.78 [95% CI, 0.42-1.46], P = .44 for young vs old), remission
Table 2. Clinical Characteristics at Randomization
Randomized Baseline Characteristics
No. (%) of Participants
Sertraline + Olanzapine (n = 64) Sertraline + Placebo (n = 62)
HDRS 17 total score, mean (SD)a 5.3 (3.6) 5.6 (3.6)
SADS
Delusion score of 1b 64 (100) 62 (100)
Hallucination score of 1c 64 (100) 62 (100)
HADS anxiety score, median (IQR)d 5.0 (2.0-8.0) 4.0 (1.0-7.0) [n = 61]
CORE total score, median (IQR)e 1.0 (0-3.0) 1.0 (0-4.8)
CIRS-G total score, median (IQR)f 3.0 (1.0-6.0) 3.0 (2.0-5.8)
MMSE, mean (SD)g 28.1 (1.9) 27.9 (2.0)
DKEFS trail making test conditions 4 vs 5 scaled score,
mean (SD)h
7.9 (3.5) (n = 61) 8.1 (3.6) (n = 59)
DKEFS color word interference condition 3 final weighted
scaled score, mean (SD)i
8.6 (2.9) (n = 60) 7.6 (2.8) (n = 58)
Barnes Akathisia Rating Scale global score >0 3.0 (4.7) 2.0 (3.2)
AIMS overall severity score >0j 2.0 (3.1) 2.0 (3.2)
Simpson-Angus Scale Total score, median (IQR)k 1.0 (0-2.0) 1.0 (0-2.0)
Study Medication Dosage at Randomization Baseline, Median (IQR), mg/d
Sertraline 150 (150- 200) 150 (150-200)
Olanzapine 15 (10-20) 15 (10-20)
Abbreviations: AIMS, Abnormal Involuntary Movement Scale17;
CIRS-G, Cumulative Illness Rating Scale for Geriatrics24; CORE, CORE
assessment of psychomotor change25; DKEFS, Delis-Kaplan Executive Function
Scale26; HADS, Hospital Anxiety and Depression Scale27; HDRS 17, 17-item
Hamilton Depression Rating Scale9; IQR, interquartile range; MMSE,
Mini-Mental State Examination14; SADS, Schedule for Affective Disorders
and Schizophrenia.10
a Range, 0 to 52; higher score indicates greater severity of depression
(a mean score of 5, remission of depression).
b Range, 1 to 7; a higher score indicates greater delusional severity
(1 indicates no delusion present).
c Range, 1 to 3; a score of 1 indicates no hallucination
(3, definite hallucination).
d Range, 0 to 21; a higher score indicates greater severity of anxiety
(7, normal range).
e Range, 0 to 54: a higher score indicates greater severity of psychomotor
change (median score of 1, minimal psychomotor change).
f Excluding the psychiatric illness category, range, 0 to 52; a higher score
indicates greater severity of cumulative illness (median score of 3, low level of
cumulative physical illness).
g Range, 0 to 30; a higher score indicates better cognitive function (mean score
of 28, normal range).
h Trail making test conditions 4 vs 5 scaled score measures cognitive flexibility
and color word interference condition 3 final weighted scaled score measures
inhibition (both are measures of executive brain function). For each of these
tasks, scaled scores range, 1 to 19, with higher scores indicating better
performance on the task (10 represents the normative populationmean).
i Scores on the global clinical assessment item of the Barnes akathisia rating
scale range from0 to 5. A higher score indicates greater severity of akathisia.
A score of 0 indicates that akathisia is not present.
j Measured tardive dyskinesia. Scores on the global severity of abnormal
movements range from0 to 4 (higher score, greater severity of abnormal
movement; 0, no abnormal movements).
k Measure extrapyramidal adverse effects. Total score, excluding the head
dropping item, ranges from0 to 36 (higher score, greater severity;
0, no extrapyramidal effects).
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vs near-remission status at RCT baseline (HR, 2.45 [95% CI,
0.98-6.13],P = .06 for remissionvsnear-remission), andstudy
site (HR, 1.53 [95% CI, 0.62-3.76], P = .36, for University of
MassachusettsvsCornell;HR, 1.09[95%CI,0.39-2.98],P = .88,
for Pittsburgh vs Cornell; and HR, 1.80 [95% CI, 0.81-4.03],
P = .15, for Toronto vs Cornell). Figure 2 shows the Kaplan-
Meier survival curves of the 2 randomized groups. Based on
theHR, thenumberneeded to treatwithsertralineplusolanza-
pine to prevent 1 relapse was 2.8.
The results were similar in a post hoc sensitivity analysis
that excluded 7 participants who had elected to discontinue
either sertraline, olanzapine or placebo, or both but had re-
mained in the study for research assessments (HR, 0.22 [95%
CI, 0.11-0.43], P < .001).
Secondary Outcomes
The effect of olanzapine on the daily rate of anthropometric
and metabolic measures (treatment × linear time interaction)
was significantly higher than placebo for weight (0.13 lb [95%
CI,0.11-0.15],adjustedP < .001), forwaistcircumference(0.009
inches [95%CI, 0.004-0.014], adjustedP = .002), and for total
cholesterol (0.29mg/dL[95%CI,0.13-0.45], adjustedP = .003).
However, the daily rate was not statistically different for low-
density lipoprotein cholesterol (0.04mg/dL [95% CI, −0.01 to
0.10], adjusted P = .57), high-density lipoprotein cholesterol
(−0.01mg/dL [95%CI,−0.03 to0.01], adjustedP = .99), triglyc-
eride(−0.153mg/dL[95%CI,−0.306to0.004],adjustedP = .25),
glucose (−0.02mg/dL[95%CI,−0.12 to0.08],adjustedP = .99),
or HbA1c levels (−0.0002mg/dL [95% CI, −0.0021 to 0.0016],
adjustedP = .99).Because the linearmixedmodels include lin-
earandquadraticeffectsof time, thedaily rateofchangeofeach
of these variables cannot be extrapolated to cumulative linear
change over the course of the clinical trial. eFigures 1 through
8 in Supplement 2 show the trajectory of each of these vari-
ables during the trial. Table 4 shows post hoc analyses of
the within-group change of each of these variables, based on
the difference in rawmeans (or, where relevant, rawmedians)
between RCT baseline and termination.
During the course of the trial, statins were started or
changed for 12 participants (6 olanzapine, 6 placebo) and
hypoglycemic agents were started or changed for 3 partici-
pants (2 olanzapine, 1 placebo). The results of post hoc sen-
sitivity analyses that examined for the possible effect of
these drugs on linear mixed-model metabolic results were
qualitatively similar to those of the analyses that included
all participants.
In post hoc analyses, there were no statistically signifi-
cant differences between treatment groups in the number of
participantswhoexperiencedan incidenthighmetabolicvalue
(Table 5), although the studymaynot have had sufficient sta-
tistical power to detect a difference.
OtherMeasures of Tolerability
Extrapyramidal Measures
The incidence of akathisia was 4.7% in the sertraline-
olanzapinegroupand4.8%in thesertraline-placebogroup.Ex-
cept for 1 participant, all were rated asmild. The incidence of
tardive dyskinesiawas0% in the sertraline-olanzapine group
and 3.2% in the sertraline-placebo group. Weekly changes in
Simpson-Angus Scale15 total scorewas significantly higher in
the sertraline-olanzapine group than the sertraline-placebo
group(0.022points [95%CI,0.009-0.036], adjustedP = .009);
eFigure 9 in Supplement 2 shows the trajectory of this vari-
able during the trial.
Adverse Effects
More than5%ofparticipants reported the followingUdvalg for
KliniskeUndersogelser scale19 adverseeffectsat leastoncedur-
ing the trial: 17.2%in thesertraline-olanzapinegroupvs4.8%in
thesertraline-placebogroupreportedweightgain;7.8%vs4.8%,
weight loss; 7.8%vs3.2%, sleepinessor sedation; 7.8%vs3.2%
orthostatic dizziness; and 3.1% vs 8.1%nausea or vomiting.
Twenty participants (31.3%) of 64 taking olanzapine and
11 (17.7%) of 62 takingplacebo experienced 1 ormore falls dur-
ing the trial.
Oneormore serious adverse events occurred in 12partici-
pants (18.8%) of 64 in the sertraline-olanzapine group and
12 (19.4%) of 62 in the sertraline-placebo group. One partici-
pant in the sertraline-olanzapine group died due to a rup-
Table 3. Number of Relapse Eventsa
Sertraline +
Olanzapine
Sertraline +
Placebo
Depression, no psychosis 5 18
Psychosis, no depression 0 1
Depression and psychosis 4 11
Suicide plan or attempt 0 3
Mania or hypomania 0 0
Psychiatric hospitalizationb 6 11
a More than 1 event occurred in some cases of relapse.
b Psychiatric hospitalization for depression, psychosis, suicidality, or mania
or hypomania.
Figure 2. Probability of Not Experiencing a Relapse
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tured aortic aneurysm; all other serious adverse events were
due to hospitalization. Of the participantswho experienced a
relapse, 6 (46.2%) of 13 in the olanzapine group and 11 (32.3%)
of 34 in the placebo group required psychiatric hospitaliza-
tion because of the relapse.
Discussion
In thisRCT involvingpatientswhosepsychotic depression re-
sponded to the combinationof sertraline andolanzapine, con-
tinuing thecombined treatment comparedwith sertralineplus
placebo reduced the risk of relapse over 36 weeks. However,
continuing olanzapine was associated with weight gain.
As hypothesized, continuation of olanzapine was more
effective than placebo in reducing relapse, with a number
needed to treat of 2.8. With placebo, the majority of relapses
occurred within the first 12 weeks after randomization,
whereas relapses among the sertraline-olanzapine group
were distributed throughout the 36-week trial. Relapses
resulted in a high frequency of psychiatric hospitalization,
highlighting the severity and cost of this disorder and the
importance in preventing relapse.
The study’s tolerability data provide information on the
risks of continuing olanzapine for psychotic depression. Con-
tinuation of olanzapine was associated with weight gain,
whereas discontinuation of olanzapine was associated with
weight loss.Mean total cholesterol decreased in both groups,
but the trajectory of declinewas greater in the placebo group.
Therewasno significant differencebetweengroups in the tra-
jectory of triglyceride, glucose, or HbA1c values.
When this study was designed, olanzapine was the only
second-generationantipsychoticwithRCTevidenceofefficacy
in the acute treatment of psychotic depression.3,4,6 Subse-
quently,Wijkstra et al31 reported that quetiapine in combina-
tion with venlafaxine was more efficacious than venlafaxine
monotherapy in the acute treatment of psychotic depres-
sion. However, their study was limited to persons aged 18 to
65 years and therefore the efficacy and tolerability of queti-
apine inolderpersonswithpsychoticdepression isnotknown.
Without evidence, equivalent efficacy of other atypical anti-
psychotics in the treatmentof psychotic depression cannot be
assumed.32 Moreover, although several other antipsychotics
are associatedwith lessweight gain thanolanzapine, they can
cause other adverse effects, such as akathisia, parkinsonism,
and insomnia, which are potentially problematic in the treat-
ment of psychotic depression.32
Limitations
This study has several limitations. First, the findings are
limited to sertraline and olanzapine. Based on retrospec-
tive data33 and a case series,34 it is possible that the study’s
finding regarding risk of relapse with olanzapine discontinu-
ation may generalize to other antipsychotic medications, but
more definitive research, using alternative medication com-
binations, is required. Second, the study does not provide
information on the optimal duration of treatment with
olanzapine following remission of psychotic depression.Ta
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Asequential discontinuationdesignwouldhavebeenmore in-
formative on how long to continue antipsychotic medication
after remission, but it would have required many more par-
ticipants and would have been more costly. Third, based on
other data,34 a 4-week taper of antipsychoticmedicationwas
chosen. It is possible that a slower taper would have been as-
sociated with a lower relapse rate. Fourth, patients were not
assessed for the presence of comorbid personality disorders.
Some personality disorders are associated with suicide at-
tempts and riskofhospitalization,35whichwere criteria for re-
lapse in this study. If randomized groups had differed in the
frequencyof personality disorders, this imbalance couldhave
affected the primary outcome. Fifth, because of early relapse
and exit from the study, 50% of the participants in the pla-
cebogroupwereobservedfor20weeksor less,whichmayhave
led to an underestimation of the reduction in weight and lip-
ids associatedwithdiscontinuationofolanzapine. Sixth, there
were no data on biomarkers of risk of relapse. Forty-five per-
cent of participants switched to placebo did not relapse, and
theybenefited fromadecline inweight and lipids. These find-
ings suggest the need to identify clinical and biological pre-
dictorsof relapse followingantipsychoticdiscontinuation; this
would allow some precision when deciding which individu-
als can be safely withdrawn from antipsychotic medication
after remission of psychotic depression.
Conclusions
Among patientswith psychotic depression in remission, con-
tinuing sertraline plus olanzapine compared with sertraline
plus placebo reduced the risk of relapse over 36 weeks. This
benefit needs to be balanced against potential adverse effects
of olanzapine, including weight gain.
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